These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11367244)

  • 1. Amprenavir: a new protease inhibitor nears approval.
    Highleyman L
    BETA; 1999 Jan; 12(1):8-9. PubMed ID: 11367244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glaxo Wellcome's two new drugs.
    Res Initiat Treat Action; 1998 Dec; 4(7):14. PubMed ID: 11366081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.
    Highleyman L
    BETA; 1999 Apr; 12(2):3. PubMed ID: 11366693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amprenavir, new protease inhibitor, approved.
    James JS
    AIDS Treat News; 1999 May; (No 318):1-3. PubMed ID: 11366454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amprenavir (Agenerase) now available in expanded access.
    AIDS Treat News; 1998 Oct; (No 304):5. PubMed ID: 11365864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug approval.
    AIDS Policy Law; 1999 Apr; 14(8):12. PubMed ID: 11366532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amprenavir (Agenerase).
    Simmons P
    Res Initiat Treat Action; 1999 Jul; 5(3):7-10. PubMed ID: 11366726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 141 (Vertex-478).
    Baker R; Bowers M
    BETA; 1997 Mar; ():5. PubMed ID: 11364529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir approved.
    STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs: amprenavir and abacavir.
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded access program begins.
    Highleyman L
    BETA; 1998 Oct; ():3. PubMed ID: 11365989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded access.
    Proj Inf Perspect; 1999 Apr; (27):13. PubMed ID: 11366730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
    Corbett AH; Kashuba AD
    Curr Opin Investig Drugs; 2002 Mar; 3(3):384-90. PubMed ID: 12054084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coming therapies: amprenavir.
    Gatell J
    Int J Clin Pract Suppl; 1999 Jun; 103():42-4. PubMed ID: 10622044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New expanded access drugs for use in combination therapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():22-3. PubMed ID: 11367085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study: new drug doesn't display cross-resistance.
    AIDS Alert; 1999 Jul; 14(7):77. PubMed ID: 11366418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
    AIDS Treat News; 1997 Dec; (No 284):4. PubMed ID: 11364914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir made available through early access program.
    AIDS Patient Care STDS; 1998 Dec; 12(12):939-40. PubMed ID: 11362067
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
    Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.